|
44 Companies |
|
53 Products |
|
53 Products |
|
65 Mechanisms of Action |
|
1 Trial |
|
216 News |
|
| 12345» |
- | Biomarker, Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Correlative Biomarker Study in Patients With Myeloproliferative Disorders (clinicaltrials.gov) - Dec 13, 2018
P=N/A, N=592, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
Recruiting --> Completed | N=860 --> 592 | Trial completion date: Jun 2019 --> Jul 2018 | Trial primary completion date: Jun 2019 --> Jul 2018
- | Trial completion, Biopsy: Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy (clinicaltrials.gov) - Jun 28, 2018
P=N/A, N=83, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting --> Completed | N=860 --> 592 | Trial completion date: Jun 2019 --> Jul 2018 | Trial primary completion date: Jun 2019 --> Jul 2018 Recruiting --> Completed
- | Trial completion, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Jun 2, 2018
P=N/A, N=80, Completed, Sponsor: Wake Forest University Health Sciences
Recruiting --> Completed Active, not recruiting --> Completed
- Daurismo (glasdegib) / Pfizer
Enrollment change, Trial termination: Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib (clinicaltrials.gov) - Apr 2, 2018
P2, N=21, Terminated, Sponsor: Pfizer
Active, not recruiting --> Completed N=222 --> 21 | Recruiting --> Terminated
- | Trial completion: Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant (clinicaltrials.gov) - Feb 1, 2018
P=N/A, N=304, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=222 --> 21 | Recruiting --> Terminated Active, not recruiting --> Completed
- ||||||| Pegasys (pegylated interferon α -2a) / Roche
Trial completion: Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) (clinicaltrials.gov) - Jan 24, 2018
P3, N=168, Completed, Sponsor: Ronald Hoffman
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment change, Trial primary completion date: Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients (clinicaltrials.gov) - Jan 19, 2018
P=N/A, N=131, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
Active, not recruiting --> Completed N=571 --> 131 | Trial primary completion date: Sep 2016 --> Jun 2016
- | Trial completion, Enrollment change, Trial primary completion date: Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients (clinicaltrials.gov) - Jan 4, 2018
P=N/A, N=571, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
N=571 --> 131 | Trial primary completion date: Sep 2016 --> Jun 2016 Recruiting --> Completed | N=400 --> 571 | Trial primary completion date: Dec 2018 --> Sep 2016
- ||||||| Jakafi (ruxolitinib) / Incyte
Trial completion, Phase classification: INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. (clinicaltrials.gov) - Dec 21, 2017
P3, N=2232, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=400 --> 571 | Trial primary completion date: Dec 2018 --> Sep 2016 No Longer Available --> Completed | Phase classification: P4 --> P3
- | fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment change: Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Sep 27, 2017
P1/2, N=147, Completed, Sponsor: OHSU Knight Cancer Institute
No Longer Available --> Completed | Phase classification: P4 --> P3 N=204 --> 147
- | Trial completion, Enrollment change, Trial primary completion date: Familial Myeloproliferative Disorders (clinicaltrials.gov) - Sep 5, 2017
P=N/A, N=17, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
N=204 --> 147 Recruiting --> Completed | N=200 --> 17 | Trial primary completion date: Jun 2017 --> Jan 2015
- | aspirin / Generic mfg., hydroxyurea / Generic mfg.
Enrollment open, Trial initiation date: FAST: Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia (clinicaltrials.gov) - Jul 26, 2017
P3, N=2250, Recruiting, Sponsor: Assistance Publique - H
Recruiting --> Completed | N=200 --> 17 | Trial primary completion date: Jun 2017 --> Jan 2015 Not yet recruiting --> Recruiting | Initiation date: Nov 2015 --> Mar 2016
- | Trial completion, Enrollment change: Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer (clinicaltrials.gov) - Jul 19, 2017
P1, N=29, Completed, Sponsor: California Cancer Consortium
Not yet recruiting --> Recruiting | Initiation date: Nov 2015 --> Mar 2016 Active, not recruiting --> Completed | N=40 --> 29
- | Jakafi (ruxolitinib) / Novartis, Incyte
Trial primary completion date: Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis (clinicaltrials.gov) - May 24, 2017
P2, N=28, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | N=40 --> 29 Trial primary completion date: Mar 2017 --> Jul 2017
- | dapsone / Generic mfg.
Enrollment change: Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone (clinicaltrials.gov) - Apr 17, 2017
P=N/A, N=41, Completed, Sponsor: Vanderbilt University
Trial primary completion date: Mar 2017 --> Jul 2017 N=200 --> 41
- ||| gandotinib (LY 2784544) / Eli Lilly
Trial completion: Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms (clinicaltrials.gov) - Apr 11, 2017
P1, N=100, Completed, Sponsor: Eli Lilly and Company
N=200 --> 41 Active, not recruiting --> Completed
- |||| Jakafi (ruxolitinib) / Novartis, Incyte
Trial completion: Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (clinicaltrials.gov) - Mar 31, 2017
P1/2, N=154, Completed, Sponsor: Incyte Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Daurismo (glasdegib) / Pfizer
Enrollment open: Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib (clinicaltrials.gov) - Feb 28, 2017
P2, N=222, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- | anagrelide CR (GALE-401) / SELLAS Life Sciences
Trial completion, Trial primary completion date: A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders (clinicaltrials.gov) - Feb 27, 2017
P2, N=18, Completed, Sponsor: Galena Biopharma, Inc.
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> May 2016
- ||| Daurismo (glasdegib) / Pfizer
Enrollment closed: Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib (clinicaltrials.gov) - Feb 13, 2017
P2, N=222, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> May 2016 Recruiting --> Active, not recruiting
- || Daurismo (glasdegib) / Pfizer
Trial primary completion date: Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib (clinicaltrials.gov) - Feb 7, 2017
P2, N=222, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2017 --> Dec 2016
- Vonjo (pacritinib) / SOBI
Enrollment change, Trial termination, Trial primary completion date: Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) (clinicaltrials.gov) - Jan 26, 2017
P2, N=4, Terminated, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Oct 2017 --> Dec 2016 N=40 --> 4 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2020 --> Jan 2017
- aspirin / Generic mfg., hydroxyurea / Generic mfg.
Trial completion, Trial primary completion date: Primary Thrombocythaemia 1 Trial (clinicaltrials.gov) - Jan 18, 2017
P=N/A, N=1398, Completed, Sponsor: University of Cambridge
N=40 --> 4 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2020 --> Jan 2017 Active, not recruiting --> Completed | Trial primary completion date: Apr 2024 --> Nov 2016
- | Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment closed, Enrollment change: Ruxolitinib Prior to Transplant in Patients With Myelofibrosis (clinicaltrials.gov) - Jan 18, 2017
P2, N=21, Active, not recruiting, Sponsor: John Mascarenhas
Active, not recruiting --> Completed | Trial primary completion date: Apr 2024 --> Nov 2016 Recruiting --> Active, not recruiting | N=86 --> 21
- ||||| Pegasys (pegylated interferon α -2a) / Roche
Enrollment closed, Enrollment change, Trial primary completion date: Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) (clinicaltrials.gov) - Jan 11, 2017
P3, N=168, Active, not recruiting, Sponsor: Ronald Hoffman
Recruiting --> Active, not recruiting | N=86 --> 21 Recruiting --> Active, not recruiting | N=300 --> 168 | Trial primary completion date: Jun 2024 --> Jun 2017
- |||| Pegasys (pegylated interferon ? -2a) / Roche
Trial completion, Enrollment change, Trial primary completion date: MPD-RC 111: Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) (clinicaltrials.gov) - Jan 11, 2017
P2, N=135, Completed, Sponsor: Ronald Hoffman
Recruiting --> Active, not recruiting | N=300 --> 168 | Trial primary completion date: Jun 2024 --> Jun 2017 Recruiting --> Completed | N=188 --> 135 | Trial primary completion date: Jun 2018 --> Dec 2016
- Trial primary completion date: Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients (clinicaltrials.gov) - Dec 23, 2016
P=N/A, N=400, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Recruiting --> Completed | N=188 --> 135 | Trial primary completion date: Jun 2018 --> Dec 2016 Trial primary completion date: Jan 2017 --> Dec 2018
- | Campath (alemtuzumab) / Sanofi
Trial completion: Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Dec 14, 2016
P1, N=20, Completed, Sponsor: Yale University
Trial primary completion date: Jan 2017 --> Dec 2018 No longer recruiting --> Completed
- daunorubicin / Generic mfg., cyclophosphamide / Generic mfg., decitabine / Generic mfg.
Trial completion: Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms (clinicaltrials.gov) - Nov 8, 2016
P2, N=455, Completed, Sponsor: Hospital Israelita Albert Einstein
No longer recruiting --> Completed Active, not recruiting --> Completed
- Sylvant (siltuximab) / Jazz
Enrollment change, Trial withdrawal: Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (clinicaltrials.gov) - Oct 25, 2016
P0, N=0, Withdrawn, Sponsor: Northwestern University
Active, not recruiting --> Completed N=12 --> 0 | Not yet recruiting --> Withdrawn
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial completion, Trial primary completion date: Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Sep 21, 2016
P1/2, N=204, Completed, Sponsor: OHSU Knight Cancer Institute
N=12 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Aug 2015
- New trial, Adverse events: OUEST: Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients (clinicaltrials.gov) - Sep 8, 2016
P=N/A, N=286, Completed, Sponsor: University Hospital, Brest
- Jakafi (ruxolitinib) / Novartis, Incyte
Trial primary completion date: Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis (clinicaltrials.gov) - Aug 26, 2016
P2, N=28, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Aug 2015 Trial primary completion date: Dec 2016 --> Mar 2017
- Trial primary completion date: Familial Myeloproliferative Disorders (clinicaltrials.gov) - Jul 28, 2016
P=N/A, N=200, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Trial primary completion date: Dec 2016 --> Mar 2017 Trial primary completion date: Jun 2016 --> Jun 2017
- Trial primary completion date: Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer (clinicaltrials.gov) - Jul 28, 2016
P1, N=40, Active, not recruiting, Sponsor: California Cancer Consortium
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Dec 2015 --> Jun 2017
- | ondansetron / Generic mfg.
Trial completion, Metastases: Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment (clinicaltrials.gov) - Jul 4, 2016
P3, N=100, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Dec 2015 --> Jun 2017 Active, not recruiting --> Completed
- Sylvant (siltuximab) / Jazz
New trial: Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (clinicaltrials.gov) - Jun 20, 2016
P0, N=12, Not yet recruiting, Sponsor: Northwestern University
- ||||||| Anathromb (anagrelide CR) / AOP Orphan Pharma
Trial completion, Enrollment change, Trial primary completion date: ARETA: Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia (clinicaltrials.gov) - May 26, 2016
P3, N=146, Completed, Sponsor: AOP Orphan Pharmaceuticals AG
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=280 --> 146 | Trial primary completion date: Mar 2016 --> Jan 2015
- Enrollment change, Trial withdrawal: Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=0, Withdrawn, Sponsor: Shandong University
Active, not recruiting --> Completed | N=280 --> 146 | Trial primary completion date: Mar 2016 --> Jan 2015 N=300 --> 0 | Not yet recruiting --> Withdrawn
- | Vonjo (pacritinib) / SOBI
Enrollment closed: Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) (clinicaltrials.gov) - Feb 16, 2016
P2, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=300 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- Biomarker, Trial primary completion date: Correlative Biomarker Study in Patients With Myeloproliferative Disorders (clinicaltrials.gov) - Feb 3, 2016
P=N/A, N=860, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Jun 2019
- Trial primary completion date: Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients (clinicaltrials.gov) - Feb 2, 2016
P=N/A, N=400, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Trial primary completion date: Dec 2015 --> Jun 2019 Trial primary completion date: Aug 2016 --> Jan 2017
- New trial: Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders (clinicaltrials.gov) - Jan 26, 2016
P=N/A, N=300, Not yet recruiting, Sponsor: Shandong University
- Jakafi (ruxolitinib) / Novartis, Incyte
Trial primary completion date: Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis (clinicaltrials.gov) - Jan 17, 2016
P2, N=28, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Aug 2016 --> Jan 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- |||| Anathromb (anagrelide CR) / AOP Orphan Pharma
Trial primary completion date: ARETA: Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia (clinicaltrials.gov) - Jan 17, 2016
P3, N=280, Active, not recruiting, Sponsor: AOP Orphan Pharmaceuticals AG
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Aug 2015 --> Mar 2016
- Trial primary completion date: Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients (clinicaltrials.gov) - Dec 25, 2015
P=N/A, N=400, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Trial primary completion date: Aug 2015 --> Mar 2016 Trial primary completion date: Aug 2015 --> Aug 2016
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen (clinicaltrials.gov) - Nov 26, 2015
P1/2, N=60, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: Aug 2011 --> Nov 2016
- || aspirin / Generic mfg., hydroxyurea / Generic mfg.
New P3 trial: FAST: Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia (clinicaltrials.gov) - Nov 24, 2015
P3, N=2250, Not yet recruiting, Sponsor: Assistance Publique - H
- Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment closed: Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis (clinicaltrials.gov) - Oct 30, 2015
P2, N=28, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Aug 2011 --> Nov 2016 Suspended --> Active, not recruiting
- luminespib (AUY922) / Ligand
Trial primary completion date: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET (clinicaltrials.gov) - Sep 24, 2015
P2, N=7, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
Suspended --> Active, not recruiting Trial primary completion date: Aug 2015 --> May 2015